Circulating IL-6, Clusterin and Irisin in Obese Subjects

Rehab Werida

Status: Completed

Conditions: Obesity

Treatments: Diagnostic Test: IL-6, Clusterin, Irisin Level

Study type: Observational

Funder types: Other

Identifiers

NCT04133896

Obesity and IR

Details and patient eligibility

About

evaluate the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes who had different classes of obesity and their sexual dimorphism also identify the association of IL-6, clusterin and irisin with insulin resistance.

Full description

Aim: Firstly, this study aimed at assessing the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes who had different classes of obesity and evaluating their sexual dimorphism and secondly evaluate the association of IL-6, clusterin and irisin with insulin resistance.

Method: This study was conducted on 176 non-diabetic subjects of both sexes. Participants were classified according to their sex into two groups; the male and female groups. The male group (88 men) was classified according to BMI into; group 1 (22 lean men), group 2 (22 class I obese men), group 3 (22 class II obese men), and group 4 (22 class III obese men). The female group (88 women) was also classified according to BMI exactly as the male group. Fasting blood glucose, fasting insulin, lipid panel, serum IL-6, clusterin and irisin levels were measured. One-way analysis of variance followed by Tukey's as post hoc test was used for comparison of variables.

Enrollment: 176 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy Female and Male
• Age matched adult non-diabetic non-smoker males and females'

Exclusion criteria

• smokers, subjects with a history of diabetes mellitus, liver, renal, thyroid, inflammatory diseases, and females on contraceptives pills. Patients on medications that can interfere with glucose or lipid metabolism (corticosteroids, anti-hyperlipidemics, non-selective beta blockers, thiazides, etc.) and subjects with organic causes of obesity were also excluded from this study.

Trial design

176 participants in 8 patient groups

Group 1 Male

Description:

group 1 (22 lean men),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 2 Male

Description:

group 2 (22 class I obese men),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 3 Male

Description:

group 3 (22class II obese men),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 4 Male

Description:

group 4 (22 class III obese men).

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 1 Female

Description:

group 1 (22 lean women),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 2 Female

Description:

group 2 (22 class I obese women),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 3 Female

Description:

group 3 (22 class II obese women),

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level

Group 4 Female

Description:

group 4 (22 class III obese women).

Treatment:

Diagnostic Test: IL-6, Clusterin, Irisin Level